Celecoxib Radiosensitizes the Human Cervical Cancer HeLa Cell Line via a Mechanism Dependent on Reduced Cyclo-Oxygenase-2 and Vascular Endothelial Growth Factor C Expression
Free accessResearch articleFirst published online February, 2012
Celecoxib Radiosensitizes the Human Cervical Cancer HeLa Cell Line via a Mechanism Dependent on Reduced Cyclo-Oxygenase-2 and Vascular Endothelial Growth Factor C Expression
OBJECTIVE: The effects of celecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor, on HeLa cervical cancer cell growth and radiosensitivity were investigated. METHODS: Cytotoxicity was quantified using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay and effects on radiosensitivity were assessed using the lethal dose, quasithreshold dose, fraction surviving after 2 Gy irradiation and the radiosensitization ratio (SER, based on average lethal dose) determined using a single-hit multitarget model. RESULTS: Celecoxib inhibited HeLa cell proliferation in a concentration- and time-dependent manner, with a half-maximal inhibitory concentration at 72 h of 44 μmol/l. Treatment with 20 μmol/l celecoxib for 72 h before irradiation was associated with an SER of 2.01. The SER of irradiated cells was 2.41 when treated with 40 μmol/l celecoxib before irradiation, 1.89 when treated simultaneously and 1.44 when treated after irradiation. Celecoxib down-regulated COX-2 and vascular endothelial growth factor C (VEGF-C) expression evaluated immunohistochemically. CONCLUSION: Celecoxib pretreatment radiosensitizes HeLa cells via a mechanism dependent on down-regulation of COX-2 and VEGF-C.
FerlayJShinHRBrayF: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer2010; 127: 2893–2917.
2.
PetignatPRoyM: Diagnosis and management of cervical cancer. BMJ2007; 335: 765–768.
3.
KararJMaityA: Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther2009; 8: 1994–2001.
4.
CaoYPrescottSM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol2002; 190: 279–286.
5.
SahinMSahinEGümüslüS: Cyclooxygenase-2 in cancer and angiogenesis. Angiology2009; 60: 242–253.
6.
TerakadoNShintaniSYanoJ: Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol2004; 40: 383–389.
7.
BansalSSJoshiABansalAK: New dosage formulations for targeted delivery of cyclooxygenase-2 inhibitors: focus on use in the elderly. Drugs Aging2007; 24: 441–451.
8.
ChenKHHsuCCSongWS: Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells. Childs Nerv Syst2010; 26: 1605–1612.
9.
GoldsteinJLSilversteinFEAgrawalNM: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol2000; 95: 1681–1690.
10.
KishiKPetersenSPetersenC: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res2000; 60: 1326–1331.
11.
LiuHXiaoJYangY: COX-2 expression is correlated with VEGF-C, lymphangiogenesis and lymph node metastasis in human cervical cancer. J Microvasc Res2011; 82: 131–140.
12.
SpringEHolmbergP: Evaluation of experimental irradiation fractionation with the single-hit, multi-target model. Acta Radiol Ther Phys Biol1968; 7: 297–306.
13.
ChengASChanHLLeungWK: Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol2004; 17: 1169–1179.
14.
ChenYJWangLSWangPH: High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol Oncol2003; 88: 379–385.
15.
MaHIChiouSHHuengDY: Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation. J Neurosurg2011; 114: 651–662.
16.
LuoWRLiLXLiSY: Influence of celecoxib on invasiveness of human high-metastatic nasopharyngeal carcinoma cell line CNE-2Z. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi2010; 45: 941–945 [in Chinese, English abstract].
17.
MilasLMasonKALiaoZ: Chemoradiotherapy: emerging treatment improvement strategies. Head Neck2003; 25: 152–167.
18.
KokiATLeahyKMMasferrerJL: Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin Investig Drugs1999; 8: 1623–1638.
19.
HansonWRAinsworthEJ: 16,16-Dimethyl prostaglandin E2 induces radioprotection in murine intestinal and hematopoietic stem cells. Radiat Res1985; 103: 196–203.
20.
de RozenowiczLRSantosRESilvaMA: Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer. Rev Col Bras Cir2010; 37: 323–327 [in English and Portuguese].
21.
WangMHeYShiL: Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol2011; 32: 171–177.
22.
MrenaJWikstenJPKokkolaA: COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol2010; 31: 1–7.
23.
XiaSZhaoYYuS: Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother Radiopharm2010; 25: 317–323.
24.
RajuUNakataEYangP: In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys2002; 54: 886–894.
25.
ShahTRyuSLeeHJ: Pronounced radiosensitization of cultured human cancer cells by COX inhibitor under acidic microenvironment. Int J Radiat Oncol Biol Phys2002; 53: 1314–1318.
26.
SettakornJKhunamornpongSSukpanK: Cyclooxygenase-2 expression in cervical squamous cell carcinoma: the significance of expression in neoplastic cells within the lymphovascular space. Asian Pac J Cancer Prev2009; 10: 1011–1014.
27.
ToomeyDPMurphyJFConlonKC: COX-2, VEGF and tumour angiogenesis. Surgeon2009; 7: 174–180.
28.
KakiuchiYTsujiSTsujiiM: Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res2002; 62: 1567–1572.
29.
SteinauerKKGibbsINingS: Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys2000; 48: 325–328.
30.
PatelMLSubbaramaiahKDuB: Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res2005; 11: 1999–2007.
31.
KimSHSongSHKimSG: Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target. J Cancer Res Clin Oncol2004; 130: 551–560.
32.
RajuUArigaHDittmannK: Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys2005; 63: 520–528.
33.
XuXYiFFuX: Effects of celecoxib on the proliferation and apoptosis of human nasopharyngeal carcinoma cell line CNE-2. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi2009; 23: 682–685 [in Chinese, English abstract].
34.
DesaiDKaushalNGandhiUH: Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib. Chem Biol Interact2010; 188: 446–456.
35.
MeharAMacanas-PirardPMizokamiA: The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. J Pharmacol Exp Ther2008; 324: 1181–1187.
36.
von RahdenBHSteinHJPühringerF: Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res2005; 65: 5038–5044.
37.
KyzasPAStefanouDAgnantisNJ: COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Mod Pathol2005; 18: 153–160.
38.
SuJLShihJYYenML: Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: A novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res2004; 64: 554–564.
